MobiHealth News December 31, 2025
The extension allows providers to continue remotely prescribing Schedule II–V controlled substances under specific conditions to prevent a disruptive “telemedicine cliff.”
The U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have issued a Fourth Temporary Extension of the COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications, allowing providers to remotely prescribe Schedule II-V controlled medications indefinitely, following at least one initial in-person medical evaluation.
“This permits the practitioner to remotely prescribe controlled substances to that patient indefinitely, regardless of how much time has passed since the initial in-person medical evaluation or whether that evaluation was for a separate medical concern, so long as such prescriptions are issued for a legitimate medical purpose while...
Today's Sponsors
Today's Sponsor